ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

Grzegorz S. Nowakowski, Annalisa Chiappella, Thomas E. Witzig, Michele Spina, Randy D. Gascoyne, Lei Zhang, Jocelyne Flament, Jacqueline Repici, Umberto Vitolo

Research output: Contribution to journalArticle

Abstract

Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), the major constituent of nongerminal center B-cell-like (non-GCB) DLBCL, is associated with poorer survival outcomes than GCB-type DLBCL. In Phase II studies, lenalidomide combined with R-CHOP (R-CHOP) improved outcomes relative to historical R-CHOP in newly diagnosed DLBCL, particularly in non-GCB cases. ROBUST (CC-5013-DLC-002) is a randomized, double-blind, global, Phase III study of oral lenalidomide (15 mg, days 1-14) plus R-CHOP21 × 6 versus placebo-R-CHOP21 × 6 in patients with previously untreated ABC-type DLBCL. Subtyping is done within 3 calendar days by central laboratory gene-expression profiling of formalin-fixed paraffin-embedded biopsy tissue. The primary end point is progression-free survival. Secondary end points include response rates, overall survival and health-related quality of life.

Original languageEnglish
Pages (from-to)1553-1563
Number of pages11
JournalFuture Oncology
Volume12
Issue number13
DOIs
Publication statusPublished - Jul 1 2016

Keywords

  • chemotherapy
  • hematologic/lymphoma
  • molecular oncology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Nowakowski, G. S., Chiappella, A., Witzig, T. E., Spina, M., Gascoyne, R. D., Zhang, L., Flament, J., Repici, J., & Vitolo, U. (2016). ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncology, 12(13), 1553-1563. https://doi.org/10.2217/fon-2016-0130